Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2/3 1

Status

Withdrawn 3

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Other 1

Conditions

Pancreatic Neoplasms 2Opioid-Induced Constipation 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × methylnaltrexone × Clear all
NCT04083651 2021-05-07

A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Bausch Health Americas, Inc.

Phase 2/3 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT04151719 2021-05-07

An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Bausch Health Americas, Inc.

Phase 3 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT00858754 2019-11-29

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

Bausch Health Americas, Inc.

Phase 4 Withdrawn
Other

Opioid-Induced Constipation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡